An Interventional, One-arm, Open Label Pilot Study to Assess the Feasibility of Dolutegravir Monotherapy in Virologically Suppressed Patients on Conventional Triple Antiretroviral Therapy of Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MONODO
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 23 Dec 2016 Status changed from recruiting to active, no longer recruiting.